Can-Fite BioPharma Ltd. (CANF)
NYSEAMERICAN: CANF · Real-Time Price · USD
2.160
-0.030 (-1.37%)
At close: Sep 10, 2026, 4:00 PM EDT
2.175
+0.015 (0.70%)
Pre-market: Sep 11, 2026, 4:12 AM EDT
Can-Fite BioPharma Employees
Can-Fite BioPharma had 5 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
5
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$81,000
Profits / Employee
-$1,910,600
Market Cap
4.88M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 5 | 0 | - |
| Dec 31, 2024 | 5 | -3 | -37.50% |
| Dec 31, 2023 | 8 | 0 | - |
| Dec 31, 2022 | 8 | 0 | - |
| Dec 31, 2021 | 8 | 0 | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| HCW Biologics | 35 |
| VivoSim Labs | 15 |
| Processa Pharmaceuticals | 12 |
| NuCana | 12 |
| Dermata Therapeutics | 9 |
| Revelation Biosciences | 9 |
| Cadrenal Therapeutics | 5 |
| Kairos Pharma | 4 |
CANF News
- 1 day ago - Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation - GlobeNewsWire
- 2 days ago - Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study - GlobeNewsWire
- 8 days ago - Can-Fite Enters Warrant Exercise Deal For $4 Mln, Shares To Be Issued At Discount; Stock Plunges - Nasdaq
- 8 days ago - CANF Looks 45.6% Undervalued on GF Value⢠Despite Challenging Fundamentals - GuruFocus
- 8 days ago - Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds - GlobeNewsWire
- 8 days ago - Can-Fite reports longer-than-anticipated survival observed in Namodenoson study - TheFly
- 8 days ago - Can-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study - GlobeNewsWire
- 13 days ago - Can-Fite BioPharma files $100M mixed securities shelf - TheFly